Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902
Top Cited Papers
- 15 November 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (22), 4224-4237
- https://doi.org/10.1200/jco.2001.19.22.4224
Abstract
PURPOSE: To evaluate whether preoperative neoadjuvant chemotherapy in patients with primary operable breast cancer results in better overall survival (OS) and relapse-free survival rates and whether preoperative chemotherapy permits more breast-conserving surgery procedures than postoperative chemotherapy. PATIENTS AND METHODS: Six hundred ninety-eight breast cancer patients (T1c, T2, T3, T4b, N0 to 1, and M0) were enrolled onto a randomized phase III trial that compared four cycles of fluorouracil, epirubicin, and cyclophosphamide administered preoperatively versus the same regimen administered postoperatively (the first cycle administered within 36 hours after surgery). Patients were followed up for OS, progression-free survival (PFS), and locoregional recurrence (LRR). RESULTS: At a median follow-up of 56 months, there was no significant difference in terms of OS (hazards ratio, 1.16; P = .38), PFS (hazards ratio, 1.15; P = .27), and time to LRR (hazards ratio, 1.13; P = .61). Fifty-seven patients (23%) were downstaged by the preoperative chemotherapy, whereas 14 patients (18%) underwent mastectomy and not the planned breast-conserving therapy. CONCLUSION: The use of preoperative chemotherapy yields similar results in terms of PFS, OS, and locoregional control compared with conventional postoperative chemotherapy. In addition, preoperative chemotherapy enables more patients to be treated with breast-conserving surgery. Because preoperative chemotherapy does not improve disease outcome compared with postoperative chemotherapy, future trials should involve quality-of-life studies to investigate whether patients will benefit from this treatment modality.Keywords
This publication has 39 references indexed in Scilit:
- High Local Recurrence Risk After Breast-Conserving Therapy in Node-Negative Premenopausal Breast Cancer Patients Is Greatly Reduced by One Course of Perioperative Chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group StudyJournal of Clinical Oncology, 2000
- Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-upAnnals Of Oncology, 1999
- Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study.Journal of Clinical Oncology, 1994
- Neoadjuvant chemotherapy in operable breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cmAnnals Of Oncology, 1991
- TOXIC EFFECTS OF EARLY ADJUVANT CHEMOTHERAPY FOR BREAST CANCERThe Lancet, 1983
- Further observations on the inhibition of tumor growth byC. parvum with cyclophosphamide.VII. Effect of treatment prior to primary tumor removal on the growth of distant tumorCancer, 1979
- Assessment of response to therapy in advanced breast cancerBritish Journal of Cancer, 1977